<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html xmlns:n1="urn:hl7-org:v3" xmlns:in="urn:lantana-com:inline-variable-data" xmlns:sdtc="urn:hl7-org:sdtc"><head>
<meta charset="utf-8"><!-- Do NOT edit this HTML directly: it was generated via an XSLT transformation from a CDA Release 2 XML document. --><title>Encounter Summary</title><style type="text/css">
body {
  color: #003366;
  background-color: #FFFFFF;
  font-family: Verdana, Tahoma, sans-serif;
  font-size: 14px;
}

a {
  color: #003366;
  background-color: #FFFFFF;
}

h1 {
  font-size: 20px;
  font-weight: bold;
}

h2 {
  font-size: 18px;
  font-weight: bold;
}

h3 {
  font-size: 14px;
  font-weight: bold;
}

h4 {
  font-size: 14px;
  font-weight: bold;
}


table {
  width: 100%;
}

th {
  background-color: #ffd700;
}

td {
  padding: 0.1cm 0.2cm;
  vertical-align: top;
  background-color: #ffffcc;
}

.h1center {
  font-size: 20px;
  font-weight: bold;
  text-align: center;
  width: 80%;
}

.header_table{
  border: 1pt inset #00008b;
}

.td_label{
  font-weight: bold;
  color: white;
}

.content_span{
 font-family: Verdana, Tahoma, sans-serif;
 display: inline;
 white-space: pre-line;
}

.td_header_role_name{
  width: 20%;
  background-color: #3399ff;
}

.td_header_role_value{
  width: 80%;
  background-color: #ccccff;
}

.Bold{
  font-weight: bold;
}

.Italics{
  font-style: italic;
}

.Underline{
  text-decoration:underline;
}

.internal_format
{
	list-style: none;
	list-style-position:outside;
	margin:0;
	padding:0;
	border:0;
	border-collapse: collapse;
}
          </style></head><body>
<h2><a name="toc">Table of Contents</a></h2><ul><li><a href="#id1">Reason for Referral</a></li><li><a href="#id2">Reason for Visit</a></li><li><a href="#id3">Encounter Details</a></li><li><a href="#id4">Social History</a></li><li><a href="#id5">Medications at Time of Discharge</a></li><li><a href="#id6">Plan of Treatment</a></li><li><a href="#id7">Procedures</a></li><li><a href="#id8">Results</a></li><li><a href="#id9">Visit Diagnoses</a></li><li><a href="#id10">Administered Medications</a></li><li><a href="#id11">Additional Health Concerns</a></li><li><a href="#id12">Care Teams</a></li></ul><hr align="left" color="teal" size="2"/><h3><a name="id1" href="#toc">Reason for Referral</a></h3><div><ul><li>Preauthorization (Emergency) - Closed: <table><colgroup><col span="4" width="25%"/></colgroup><thead><tr><th>Specialty</th><th>Diagnoses / Procedures</th><th>Referred By Contact</th><th>Referred To Contact</th></tr></thead><tbody><tr><td>Radiology</td><td><p>Diagnoses</p><p>Prostate cancer (HCC)</p><p>BRCA gene mutation positive in male</p><br/><p>Procedures</p><p>MRI pelvis with and without contrast</p></td><td><p>[REDACTED], MD</p><p>[REDACTED]</p><p>[REDACTED][REDACTED]</p><p>Phone: [REDACTED]</p><p>Fax: [REDACTED]</p></td><td><p/></td></tr></tbody></table><table><colgroup><col width="13%"/><col width="12%"/><col width="25%"/><col width="13%"/><col width="12%"/><col width="13%"/><col width="12%"/></colgroup><thead><tr><th>Referral ID</th><th>Status</th><th>Reason</th><th>Start Date</th><th>Expiration Date</th><th>Visits Requested</th><th>Visits Authorized</th></tr></thead><tbody><tr><td>19333639</td><td class="xflagData">Closed</td><td/><td>[REDACTED]</td><td>[REDACTED]</td><td>1</td><td>1</td></tr></tbody></table><br/><p>Electronically signed by [REDACTED] MD at [REDACTED] 11:50 AM EDT</p></li></ul></div><h3><a name="id2" href="#toc">Reason for Visit</a></h3><div><ul><li>Preauthorization (Emergency) - Closed: <table><colgroup><col span="4" width="25%"/></colgroup><thead><tr><th>Specialty</th><th>Diagnoses / Procedures</th><th>Referred By Contact</th><th>Referred To Contact</th></tr></thead><tbody><tr><td>Radiology</td><td><p>Diagnoses</p><p>Prostate cancer (HCC)</p><p>BRCA gene mutation positive in male</p><br/><p>Procedures</p><p>MRI pelvis with and without contrast</p></td><td><p>[REDACTED], MD</p><p>[REDACTED]</p><p>[REDACTED][REDACTED]</p><p>Phone: [REDACTED]</p><p>Fax: [REDACTED]</p></td><td><p/></td></tr></tbody></table><table><colgroup><col width="13%"/><col width="12%"/><col width="25%"/><col width="13%"/><col width="12%"/><col width="13%"/><col width="12%"/></colgroup><thead><tr><th>Referral ID</th><th>Status</th><th>Reason</th><th>Start Date</th><th>Expiration Date</th><th>Visits Requested</th><th>Visits Authorized</th></tr></thead><tbody><tr><td>19333639</td><td class="xflagData">Closed</td><td/><td>[REDACTED]</td><td>[REDACTED]</td><td>1</td><td>1</td></tr></tbody></table><br/></li></ul></div><h3><a name="id3" href="#toc">Encounter Details</a></h3><div><table><colgroup><col width="10%"/><col width="15%"/><col span="3" width="25%"/></colgroup><thead><tr><th>Date</th><th>Type</th><th>Department</th><th>Care Team (Latest Contact Info)</th><th>Description</th></tr></thead><tbody><tr ID="encounter3" class="xRowNormal"><td>[REDACTED] 11:50 AM EDT - [REDACTED] 11:59 PM EDT</td><td ID="encounter3type">Hospital Encounter</td><td><p>UHealth [REDACTED] Imaging Center MRI</p><p>[REDACTED]</p><p>[REDACTED]</p><p>[REDACTED]</p></td><td><p>[REDACTED], MD</p><p>[REDACTED]</p><p>[REDACTED]-5701</p><p>[REDACTED] (Work)</p><p>[REDACTED] (Fax)</p></td><td><content>Prostate cancer (HCC); <br/>BRCA gene mutation positive in male</content><br/>Discharge Disposition: Home or Self Care - 01</td></tr></tbody></table></div><h3><a name="id4" href="#toc">Social History</a></h3><div><table ID="sochist8"><colgroup><col span="2" width="25%"/><col width="13%"/><col width="12%"/><col width="25%"/></colgroup><thead><tr><th>Tobacco Use</th><th>Types</th><th>Packs/Day</th><th>Years Used</th><th>Date</th></tr></thead><tbody><tr><td>Smoking Tobacco: Never</td><td/><td ID="sochist8packsperday"/><td/><td/></tr><tr ID="sochist8smokeless" class="xRowAlt"><td>Smokeless Tobacco: Never</td><td/><td/><td/><td/></tr></tbody></table><table><colgroup><col span="2" width="25%"/><col width="50%"/></colgroup><thead><tr><th>Alcohol Use</th><th>Standard Drinks/Week</th><th>Comments</th></tr></thead><tbody><tr><td ID="alcoholStatus">Not Currently</td><td>0 (1 standard drink = 0.6 oz pure alcohol)</td><td/></tr></tbody></table><table ID="sdohassess1"><colgroup><col width="50%"/><col span="2" width="25%"/></colgroup><thead><tr><th>Humiliation, Afraid, Rape, and Kick questionnaire</th><th>Answer</th><th>Date Recorded</th></tr></thead><tbody><tr ID="sdohassess1pair1"><td ID="sdohassess1pair1ques">Within the last year, have you been afraid of your partner or ex-partner?</td><td ID="sdohassess1pair1ans">No</td><td>[REDACTED]</td></tr><tr ID="sdohassess1pair2"><td ID="sdohassess1pair2ques">Within the last year, have you been humiliated or emotionally abused in other ways by your partner or ex-partner?</td><td ID="sdohassess1pair2ans">No</td><td>[REDACTED]</td></tr><tr ID="sdohassess1pair3"><td ID="sdohassess1pair3ques">Within the last year, have you been kicked, hit, slapped, or otherwise physically hurt by your partner or ex-partner?</td><td ID="sdohassess1pair3ans">No</td><td>[REDACTED]</td></tr><tr ID="sdohassess1pair4"><td ID="sdohassess1pair4ques">Within the last year, have you been raped or forced to have any kind of sexual activity by your partner or ex-partner?</td><td ID="sdohassess1pair4ans">No</td><td>[REDACTED]</td></tr></tbody></table><table ID="sdohassess2"><colgroup><col width="50%"/><col span="2" width="25%"/></colgroup><thead><tr><th>Social Connection and Isolation Panel [NHANES]</th><th>Answer</th><th>Date Recorded</th></tr></thead><tbody><tr ID="sdohassess2pair1"><td ID="sdohassess2pair1ques">In a typical week, how many times do you talk on the phone with family, friends, or neighbors?</td><td ID="sdohassess2pair1ans">More than three times a week</td><td>[REDACTED]</td></tr><tr ID="sdohassess2pair2"><td ID="sdohassess2pair2ques">How often do you get together with friends or relatives?</td><td ID="sdohassess2pair2ans">More than three times a week</td><td>[REDACTED]</td></tr><tr ID="sdohassess2pair3"><td ID="sdohassess2pair3ques">How often do you attend church or religious services?</td><td ID="sdohassess2pair3ans">Patient declined</td><td>[REDACTED]</td></tr><tr ID="sdohassess2pair4"><td ID="sdohassess2pair4ques">Do you belong to any clubs or organizations such as church groups, unions, fraternal or athletic groups, or school groups?</td><td ID="sdohassess2pair4ans">Patient declined</td><td>[REDACTED]</td></tr><tr ID="sdohassess2pair5"><td ID="sdohassess2pair5ques">How often do you attend meetings of the clubs or organizations you belong to?</td><td ID="sdohassess2pair5ans">Patient declined</td><td>[REDACTED]</td></tr><tr ID="sdohassess2pair6"><td ID="sdohassess2pair6ques">Marital Status</td><td ID="sdohassess2pair6ans">Not on file</td><td>[REDACTED]</td></tr></tbody></table><table ID="sdohassess3"><colgroup><col width="50%"/><col span="2" width="25%"/></colgroup><thead><tr><th>AUDIT-C</th><th>Answer</th><th>Date Recorded</th></tr></thead><tbody><tr ID="sdohassess3pair1"><td ID="sdohassess3pair1ques">Q1: How often do you have a drink containing alcohol?</td><td ID="sdohassess3pair1ans">Never</td><td>[REDACTED]</td></tr><tr ID="sdohassess3pair2"><td ID="sdohassess3pair2ques">Average Number of Drinks</td><td ID="sdohassess3pair2ans">Not on file</td><td>[REDACTED]</td></tr><tr ID="sdohassess3pair3"><td ID="sdohassess3pair3ques">Q3: How often do you have six or more drinks on one occasion?</td><td ID="sdohassess3pair3ans">Never</td><td>[REDACTED]</td></tr></tbody></table><table ID="sdohassess5"><colgroup><col width="50%"/><col span="2" width="25%"/></colgroup><thead><tr><th>Overall Financial Resource Strain (CARDIA)</th><th>Answer</th><th>Date Recorded</th></tr></thead><tbody><tr ID="sdohassess5pair1"><td ID="sdohassess5pair1ques">How hard is it for you to pay for the very basics like food, housing, medical care, and heating?</td><td ID="sdohassess5pair1ans">Not hard at all</td><td>[REDACTED]</td></tr></tbody></table><table ID="sdohassess6"><colgroup><col width="50%"/><col span="2" width="25%"/></colgroup><thead><tr><th>PHQ-2</th><th>Answer</th><th>Date Recorded</th></tr></thead><tbody><tr ID="sdohassess6pair1"><td ID="sdohassess6pair1ques">PHQ-9 Total Score</td><td ID="sdohassess6pair1ans">0</td><td>[REDACTED]</td></tr></tbody></table><table ID="sdohassess7"><colgroup><col width="50%"/><col span="2" width="25%"/></colgroup><thead><tr><th>Finnish Institute of Occupational Health - Occupational Stress Questionnaire</th><th>Answer</th><th>Date Recorded</th></tr></thead><tbody><tr ID="sdohassess7pair1"><td ID="sdohassess7pair1ques">Do you feel stress - tense, restless, nervous, or anxious, or unable to sleep at night because your mind is troubled all the time - these days?</td><td ID="sdohassess7pair1ans">Not at all</td><td>[REDACTED]</td></tr></tbody></table><table ID="sdohassess8"><colgroup><col width="50%"/><col span="2" width="25%"/></colgroup><thead><tr><th>Hunger Vital Sign</th><th>Answer</th><th>Date Recorded</th></tr></thead><tbody><tr ID="sdohassess8pair1"><td ID="sdohassess8pair1ques">Within the past 12 months, you worried that your food would run out before you got the money to buy more.</td><td ID="sdohassess8pair1ans">Never true</td><td>[REDACTED]</td></tr><tr ID="sdohassess8pair2"><td ID="sdohassess8pair2ques">Within the past 12 months, the food you bought just didn't last and you didn't have money to get more.</td><td ID="sdohassess8pair2ans">Never true</td><td>[REDACTED]</td></tr></tbody></table><table ID="sdohassess9"><colgroup><col width="50%"/><col span="2" width="25%"/></colgroup><thead><tr><th>PRAPARE - Transportation</th><th>Answer</th><th>Date Recorded</th></tr></thead><tbody><tr ID="sdohassess9pair1"><td ID="sdohassess9pair1ques">In the past 12 months, has lack of transportation kept you from medical appointments or from getting medications?</td><td ID="sdohassess9pair1ans">No</td><td>[REDACTED]</td></tr><tr ID="sdohassess9pair2"><td ID="sdohassess9pair2ques">In the past 12 months, has lack of transportation kept you from meetings, work, or from getting things needed for daily living?</td><td ID="sdohassess9pair2ans">No</td><td>[REDACTED]</td></tr></tbody></table><table><colgroup><col width="50%"/><col span="2" width="25%"/></colgroup><thead><tr><th>Sex and Gender Information</th><th>Value</th><th>Date Recorded</th></tr></thead><tbody><tr ID="BirthSex11"><td>Sex Assigned at Birth</td><td ID="BirthSex11Value">Male</td><td>[REDACTED] 11:31 AM EST</td></tr><tr ID="GenderIdentity9"><td>Gender Identity</td><td ID="GenderIdentity9Value">Male</td><td>[REDACTED] 11:31 AM EST</td></tr><tr ID="SexualOrientation10"><td>Sexual Orientation</td><td ID="SexualOrientation10Value">Straight</td><td>[REDACTED] 11:31 AM EST</td></tr></tbody></table><table><colgroup><col span="2" width="25%"/><col width="50%"/></colgroup><thead><tr><th>Job Start Date</th><th>Occupation</th><th>Industry</th></tr></thead><tbody><tr><td>Not on file</td><td ID="sochist12">Not on file</td><td ID="sochist13">Not on file</td></tr></tbody></table>documented as of this encounter</div><h3><a name="id5" href="#toc">Medications at Time of Discharge</a></h3><div><table><colgroup><col span="2" width="25%"/><col width="13%"/><col span="2" width="12%"/><col width="13%"/></colgroup><thead><tr><th>Medication</th><th>Sig</th><th>Dispensed</th><th>Refills</th><th>Start Date</th><th>End Date</th></tr></thead><tbody><tr ID="dcrx23" class="xRowNormal"><td><p>CALCIUM-VITAMIN D PO</p></td><td ID="sig23">Take 2 tablets by mouth daily.</td><td/><td>0</td><td/><td/></tr><tr ID="dcrx36" class="xRowAlt"><td><p>amlodipine-olmesartan (AZOR) 10-40 MG per tablet</p></td><td ID="sig36">Take 1 tablet by mouth daily.</td><td/><td>0</td><td>[REDACTED]</td><td/></tr><tr ID="dcrx37" class="xRowNormal"><td><p>finasteride (PROSCAR) 5 MG tablet</p></td><td ID="sig37">Take 5 mg by mouth daily.</td><td/><td>0</td><td>[REDACTED]</td><td/></tr><tr ID="dcrx38" class="xRowAlt"><td><p>tamsulosin (FLOMAX) 0.4 MG CAPS capsule</p></td><td ID="sig38">Take 0.4 mg by mouth daily.</td><td/><td>0</td><td>[REDACTED]</td><td/></tr><tr ID="dcrx21" class="xRowNormal"><td><p>abiraterone (ZYTIGA) 250 MG tablet</p><content class="xallIndent">Indications: <span class="content_span">Metastatic Malignant Neoplasm of Prostate</span></content></td><td ID="sig21">Take 4 tablets by mouth daily for 90 days. Take on an empty stomach  Indications: Cancer of Prostate that has Spread to Other Part of Body</td><td><p>360 tablet</p></td><td>0</td><td>[REDACTED]</td><td>[REDACTED]</td></tr><tr ID="dcrx24" class="xRowAlt"><td><p>abiraterone (ZYTIGA) 250 MG tablet</p><content class="xallIndent">Indications: <span class="content_span">Metastatic Malignant Neoplasm of Prostate</span></content></td><td ID="sig24">Take 4 tablets by mouth daily for 90 days. Take on an empty stomach  Indications: Cancer of Prostate that has Spread to Other Part of Body</td><td><p>360 tablet</p></td><td>0</td><td>[REDACTED]</td><td>[REDACTED]</td></tr><tr ID="dcrx26" class="xRowNormal"><td><p>abiraterone (ZYTIGA) 250 MG tablet</p><content class="xallIndent">Indications: <span class="content_span">Metastatic Malignant Neoplasm of Prostate</span></content></td><td ID="sig26">Take 4 tablets by mouth daily for 90 days. Take on an empty stomach  Indications: Cancer of Prostate that has Spread to Other Part of Body</td><td><p>360 tablet</p></td><td>0</td><td>[REDACTED]</td><td>[REDACTED]</td></tr><tr ID="dcrx28" class="xRowAlt"><td><p>abiraterone (ZYTIGA) 250 MG tablet</p><content class="xallIndent">Indications: <span class="content_span">Metastatic Malignant Neoplasm of Prostate</span></content></td><td ID="sig28">Take 4 tablets by mouth daily for 90 days. Take on an empty stomach  Indications: Cancer of Prostate that has Spread to Other Part of Body</td><td><p>360 tablet</p></td><td>0</td><td>[REDACTED]</td><td>[REDACTED]</td></tr><tr ID="dcrx30" class="xRowNormal"><td><p>sulfamethoxazole-trimethoprim (BACTRIM DS) 800-160 MG per tablet</p></td><td ID="sig30">Take 1 tablet by mouth 2 times daily.</td><td/><td>0</td><td>[REDACTED]</td><td>[REDACTED]</td></tr><tr ID="dcrx31" class="xRowAlt"><td><p>lactulose (CHRONULAC) 10 GM/15ML solution</p></td><td ID="sig31">GIVE 30ML BY MOUTH 3 TIMES DAILY FOR 30 DAYS</td><td/><td>0</td><td>[REDACTED]</td><td>[REDACTED]</td></tr><tr ID="dcrx32" class="xRowNormal"><td><p>predniSONE (DELTASONE) 5 MG tablet</p><content class="xallIndent">Indications: <span class="content_span">Prostate cancer (HCC)</span></content></td><td ID="sig32">Take 1 tablet by mouth 2 times daily. Take only while on abiraterone</td><td><p>180 tablet</p></td><td>1</td><td>[REDACTED]</td><td>[REDACTED]</td></tr><tr ID="dcrx34" class="xRowAlt"><td><p>VITAMIN D, ERGOCALCIFEROL, PO</p></td><td ID="sig34">Take 1,000 Units by mouth daily. With calcium</td><td/><td>0</td><td/><td>[REDACTED]</td></tr><tr ID="dcrx35" class="xRowNormal"><td><p>Vitamin D3 (Cholecalciferol) 25 MCG (1000 UT) tablet</p></td><td ID="sig35">Take 1,000 Units by mouth daily.</td><td/><td>0</td><td/><td>[REDACTED]</td></tr><tr ID="dcrx39" class="xRowAlt"><td><p>Livalo 2 MG TABS</p></td><td ID="sig39">Take 1 tablet by mouth daily.</td><td/><td>0</td><td>[REDACTED]</td><td>[REDACTED]</td></tr></tbody></table>documented as of this encounter</div><h3><a name="id6" href="#toc">Plan of Treatment</a></h3><div><table><span style="font-weight:bold; ">Upcoming Encounters</span><colgroup><col width="10%"/><col width="15%"/><col span="3" width="25%"/></colgroup><thead><tr><th>Date</th><th>Type</th><th>Department</th><th>Care Team (Latest Contact Info)</th><th>Description</th></tr></thead><tbody><tr ID="encounter53" class="xRowNormal"><td>[REDACTED]  8:15 AM EDT</td><td ID="encounter53type">Appointment</td><td><p>UHealth [REDACTED] at [REDACTED]</p><p>[REDACTED][REDACTED]</p><p>STE 100</p><p>[REDACTED]</p><p>[REDACTED]</p></td><td><p>[REDACTED], MD</p><p>[REDACTED]</p><p>[REDACTED]-5701</p><p>[REDACTED] (Work)</p><p>[REDACTED] (Fax)</p></td><td/></tr><tr ID="encounter52" class="xRowAlt"><td>[REDACTED] 10:15 AM EDT</td><td ID="encounter52type">Appointment</td><td><p>UHealth [REDACTED] at [REDACTED]</p><p>[REDACTED][REDACTED]</p><p>STE 100</p><p>[REDACTED]</p><p>[REDACTED]</p></td><td><p>[REDACTED], MD</p><p>[REDACTED]</p><p>[REDACTED]-5701</p><p>[REDACTED] (Work)</p><p>[REDACTED] (Fax)</p></td><td/></tr><tr ID="encounter51" class="xRowNormal"><td>[REDACTED] 11:00 AM EDT</td><td ID="encounter51type">Procedure visit</td><td><p>UHealth Urology at Plantation</p><p>[REDACTED]</p><p>PLANTATION, FL 33324</p><p>[REDACTED]</p></td><td><p>[REDACTED], MD</p><p>[REDACTED]</p><p>Suite 309</p><p>[REDACTED]-2137</p><p>[REDACTED] (Work)</p><p>[REDACTED] (Fax)</p></td><td/></tr><tr ID="encounter50" class="xRowAlt"><td>[REDACTED] 10:40 AM EDT</td><td ID="encounter50type">Office Visit</td><td><p>UHealth Oncology at [REDACTED] 2</p><p>[REDACTED]</p><p>Suite 202</p><p>CORAL SPRINGS, FL 33065</p><p>[REDACTED]</p></td><td><p>[REDACTED], MD</p><p>[REDACTED]</p><p>[REDACTED]-5701</p><p>[REDACTED] (Work)</p><p>[REDACTED] (Fax)</p></td><td/></tr><tr ID="encounter49" class="xRowNormal"><td>[REDACTED] 10:00 AM EDT</td><td ID="encounter49type">Appointment</td><td><p>UMHC [REDACTED] at UHealth Deerfield Beach Radiation Oncology</p><p>[REDACTED][REDACTED]</p><p>STE 100</p><p>[REDACTED]</p><p>[REDACTED]</p></td><td><p>[REDACTED], MD</p><p>[REDACTED][REDACTED]</p><[REDACTED][REDACTED]</p><p>[REDACTED] (Work)</p><p>[REDACTED] (Fax)</p></td><td>Discharge Disposition: Home or Self Care - 01</td></tr></tbody></table>documented as of this encounter</div><h3><a name="id7" href="#toc">Procedures</a></h3><div><table><colgroup><col width="25%"/><col width="10%"/><col width="15%"/><col span="2" width="25%"/></colgroup><thead><tr><th>Procedure Name</th><th>Priority</th><th>Date/Time</th><th>Associated Diagnosis</th><th>Comments</th></tr></thead><tbody><tr ID="procedure58" class="xRowNormal"><td><span class="content_span">MRI PELVIS W PLUS WO CONTRAST</span></td><td>STAT</td><td>[REDACTED]  1:49 PM EDT</td><td><p>Prostate cancer (HCC)</p><p>BRCA gene mutation positive in male</p></td><td><p>Results for this procedure are in the <span class="xLink2-Result.1.2.840.114350.1.13.243.2.7.2.798268.209943017">results section</span>.</p></td></tr></tbody></table>documented in this encounter</div><h3><a name="id8" href="#toc">Results</a></h3><div><ul><li>MRI pelvis with and without contrast ([REDACTED]  1:49 PM EDT): <table><colgroup><col span="2" width="25%"/><col width="50%"/></colgroup><thead><tr><th>Anatomical Region</th><th>Laterality</th><th>Modality</th></tr></thead><tbody><tr><td>Pelvis</td><td/><td>Magnetic Resonance</td></tr></tbody></table><table><colgroup><col span="5" width="20%"/></colgroup><thead><tr><th>Specimen (Source)</th><th>Anatomical Location / Laterality</th><th>Collection Method / Volume</th><th>Collection Time</th><th>Received Time</th></tr></thead><tbody><tr class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.243.2.7.2.798268.209943017.Specimen"/><td/><td/><td>[REDACTED]  2:07 PM EDT</td><td/></tr></tbody></table><table><thead><tr><th>Impressions</th></tr></thead><tbody><tr><td class="xpre"><p>[REDACTED]  8:39 PM EDT</p><p><span class="content_span">1. Posttreatment changes of the prostate gland with residual intermediate to low T2 signal changes involving the transition and peripheral zone mostly at the base and mid gland. The gland is otherwise atrophic. There remains intravesicular extension of </span><br/><span class="content_span">tumor and persistent involvement of the seminal vesicles.</span><br/><span class="content_span">2. Heterogenous enhancement of the bony pelvis, acetabula, and bilateral femoral heads, in keeping with known osseous metastasis.</span><br/><span class="content_span"> </span><br/><span class="content_span">I personally reviewed the images and the resident's/fellow's findings and agree with the final report.</span></p></td></tr></tbody></table><table><thead><tr><th>Narrative</th></tr></thead><tbody><tr><td class="xpre"><p>[REDACTED]  8:39 PM EDT</p><p><span class="content_span"> </span><br/><span class="content_span">PROCEDURE: Enhanced , Unenhanced  MRI Pelvis</span><br/><span class="content_span"> </span><br/><span class="content_span">CLINICAL INDICATION: Prostate cancer suspected. History of metastatic prostate cancer, with an MRI on 9/2022 showing a large BI-RADS 5 lesion with SV and bladder invasion, pelvic lymphadenopathy, and bone lesions. Pathology report shows 7 cores GS 4+4.</span><br/><span class="content_span"> </span><br/><span class="content_span">TECHNIQUE: Using a body phased array coil small field-of-view imaging of the prostate was performed using the following sequences; [axial T1-weighted, axial T2-weighted, sagittal T2-weighted, coronal T2-weighted, diffusion-weighted]. Axial T1-weighted </span><br/><span class="content_span">images [with fat suppression] through the prostate were obtained before and [dynamically] after the intravenous administration of GADOBENATE DIMEGLUMINE 529 MG/[REDACTED] SOLN 18 mL.</span><br/><span class="content_span">Using a large field-of-view, the entire pelvis to the level of the aortic bifurcation was imaged with the following sequences fat suppressed T2-weighted, Axial T1-weighted images ]</span><br/><span class="content_span">Postprocessing images with DynaCAD software were obtained and submitted for analysis.</span><br/><span class="content_span"> </span><br/><span class="content_span">COMPARISON: CT abdomen on [REDACTED] and MR prostate on [REDACTED]</span><br/><span class="content_span"> </span><br/><span class="content_span">PSA level: 0.29 ng/ mL on [REDACTED]</span><br/><span class="content_span"> </span><br/><span class="content_span">FINDINGS:</span><br/><span class="content_span">Prostate Size: 4.5 x 2.5 x 3.1 cm. </span><br/><span class="content_span">Volume:  18 cc</span><br/><span class="content_span">PSA density 0.02 ng/mL/cm3</span><br/><span class="content_span"> </span><br/><span class="content_span">Prostate:</span><br/><span class="content_span">*  Posttreatment changes with significant decrease in size of the remnant prostate. T2 images demonstrate residual heterogenous T2 signal throughout the remnant prostate transition and peripheral zone. Inherent T1 hyperintense signal changes of the left </span><br/><span class="content_span">prostate base, likely secondary to chronic blood products. The remnant prostate demonstrates heterogenous signal enhancement. No evidence of diffusion restriction. </span><br/><span class="content_span"> </span><br/><span class="content_span">Extraprostatic extension: Breach of the capsule with evidence of direct tumor extension</span><br/><span class="content_span"> </span><br/><span class="content_span">Seminal vesicles: Diffusely T2 hypointense signal in the bilateral seminal vesicles, likely secondary to posttreatment effects. High T1 signal in the bilateral seminal vesicles and ejaculatory ducts, likely secondary to chronic blood products.</span><br/><span class="content_span"> </span><br/><span class="content_span">Bladder: Partially distended, with nodular intermediate T2 signal intensity of the left posterior bladder wall, difficult to separate from the prostate, could be secondary to involvement of the bladder wall. </span><br/><span class="content_span"> </span><br/><span class="content_span">Lymphadenopathy: No significant lymphadenopathy by size criteria. Persistent right iliac vessel lymph node measuring 5 mm in short axis.</span><br/><span class="content_span"> </span><br/><span class="content_span">Bones: Heterogenous appearance of the pelvis, acetabula, and bilateral femoral heads with heterogenous enhancement, in keeping with known osseous metastasis.</span><br/><span class="content_span"> </span><br/><span class="content_span">Other: Visualized segments of the rectum are unremarkable.</span><br/><span class="content_span"> </span></p></td></tr></tbody></table><table><thead><tr><th>Procedure Note</th></tr></thead><tbody><tr><td class="xnoIndent" ID="Result.1.2.840.114350.1.13.243.2.7.2.798268.209943017.ProcedureNote2550851610"><p>Phillibert, [REDACTED], MD - [REDACTED]</p><content><span class="xLabel">Formatting of this note might be different from the original.</span><br/><br/><span class="content_span">PROCEDURE: Enhanced , Unenhanced  MRI Pelvis</span><br/><br/><span class="content_span">CLINICAL INDICATION: Prostate cancer suspected. History of metastatic </span><span class="content_span">prostate cancer, with an MRI on 9/2022 showing a large BI-RADS 5 lesion </span><span class="content_span">with SV and bladder invasion, pelvic lymphadenopathy, and bone lesions. </span><span class="content_span">Pathology report shows 7 cores GS 4+4.</span><br/><br/><span class="content_span">TECHNIQUE: Using a body phased array coil small field-of-view imaging of </span><span class="content_span">the prostate was performed using the following sequences; [axial </span><span class="content_span">T1-weighted, axial T2-weighted, sagittal T2-weighted, coronal T2-weighted, </span><span class="content_span">diffusion-weighted]. Axial T1-weighted </span><br/><span class="content_span">images [with fat suppression] through the prostate were obtained before </span><span class="content_span">and [dynamically] after the intravenous administration of GADOBENATE </span><span class="content_span">DIMEGLUMINE 529 MG/[REDACTED] SOLN 18 mL.</span><br/><span class="content_span">Using a large field-of-view, the entire pelvis to the level of the aortic </span><span class="content_span">bifurcation was imaged with the following sequences fat suppressed </span><span class="content_span">T2-weighted, Axial T1-weighted images ]</span><br/><span class="content_span">Postprocessing images with DynaCAD software were obtained and submitted </span><span class="content_span">for analysis.</span><br/><br/><span class="content_span">COMPARISON: CT abdomen on [REDACTED] and MR prostate on [REDACTED]</span><br/><br/><span class="content_span">PSA level: 0.29 ng/ mL on [REDACTED]</span><br/><br/><span class="content_span">FINDINGS:</span><br/><span class="content_span">Prostate Size: 4.5 x 2.5 x 3.1 cm. </span><br/><span class="content_span">Volume:  18 cc</span><br/><span class="content_span">PSA density 0.02 ng/mL/cm3</span><br/><br/><span class="content_span">Prostate:</span><br/><span class="content_span">*  Posttreatment changes with significant decrease in size of the remnant </span><span class="content_span">prostate. T2 images demonstrate residual heterogenous T2 signal throughout </span><span class="content_span">the remnant prostate transition and peripheral zone. Inherent T1 </span><span class="content_span">hyperintense signal changes of the left </span><br/><span class="content_span">prostate base, likely secondary to chronic blood products. The remnant </span><span class="content_span">prostate demonstrates heterogenous signal enhancement. No evidence of </span><span class="content_span">diffusion restriction. </span><br/><br/><span class="content_span">Extraprostatic extension: Breach of the capsule with evidence of direct </span><span class="content_span">tumor extension</span><br/><br/><span class="content_span">Seminal vesicles: Diffusely T2 hypointense signal in the bilateral seminal </span><span class="content_span">vesicles, likely secondary to posttreatment effects. High T1 signal in the </span><span class="content_span">bilateral seminal vesicles and ejaculatory ducts, likely secondary to </span><span class="content_span">chronic blood products.</span><br/><br/><span class="content_span">Bladder: Partially distended, with nodular intermediate T2 signal </span><span class="content_span">intensity of the left posterior bladder wall, difficult to separate from </span><span class="content_span">the prostate, could be secondary to involvement of the bladder wall. </span><br/><br/><span class="content_span">Lymphadenopathy: No significant lymphadenopathy by size criteria. </span><span class="content_span">Persistent right iliac vessel lymph node measuring 5 mm in short axis.</span><br/><br/><span class="content_span">Bones: Heterogenous appearance of the pelvis, acetabula, and bilateral </span><span class="content_span">femoral heads with heterogenous enhancement, in keeping with known osseous </span><span class="content_span">metastasis.</span><br/><br/><span class="content_span">Other: Visualized segments of the rectum are unremarkable.</span><br/><br/><span class="content_span">IMPRESSION:</span><br/><span class="content_span">1. Posttreatment changes of the prostate gland with residual intermediate </span><span class="content_span">to low T2 signal changes involving the transition and peripheral zone </span><span class="content_span">mostly at the base and mid gland. The gland is otherwise atrophic. There </span><span class="content_span">remains intravesicular extension of </span><br/><span class="content_span">tumor and persistent involvement of the seminal vesicles.</span><br/><span class="content_span">2. Heterogenous enhancement of the bony pelvis, acetabula, and bilateral </span><span class="content_span">femoral heads, in keeping with known osseous metastasis.</span><br/><br/><span class="content_span">I personally reviewed the images and the resident's/fellow's findings and </span><span class="content_span">agree with the final report.</span></content><br/></td></tr></tbody></table><table><colgroup><col width="20%"/><col width="80%"/></colgroup><thead><tr><th>Authorizing Provider</th><th>Result Type</th></tr></thead><tbody><tr><td>[REDACTED] MD</td><td>IMG MRI ORDERABLES</td></tr></tbody></table></li></ul>documented in this encounter</div><h3><a name="id9" href="#toc">Visit Diagnoses</a></h3><div><table><colgroup><col width="100%"/></colgroup><thead><tr><th>Diagnosis</th></tr></thead><tbody><tr ID="vdx4" class="xRowNormal"><td><p><span class="content_span">Prostate cancer (HCC)</span></p><p>Malignant neoplasm of prostate</p></td></tr><tr ID="vdx5" class="xRowAlt"><td><p><span class="content_span">BRCA gene mutation positive in male</span></p></td></tr></tbody></table>documented in this encounter</div><h3><a name="id10" href="#toc">Administered Medications</a></h3><div><table ID="admMedTable64"><span style="font-weight:bold; ">Inactive Administered Medications - up to 3 most recent administrations</span><colgroup><col width="40%"/><col span="5" width="12%"/></colgroup><thead><tr><th>Medication Order</th><th>MAR Action</th><th>Action Date</th><th>Dose</th><th>Rate</th><th>Site</th></tr></thead><tbody><tr class="xRowNormal xmedRow"><td class="Rrule" rowspan="1"><p>gadobenate dimeglumine (MULTIHANCE) 529 MG/ML injection</p><p>Starting [REDACTED][REDACTED] at 1155, For 1 dose</p></td><td>Contrast Given</td><td>[REDACTED]  1:55 PM EDT</td><td>18 mLs</td><td> </td><td>Right Arm</td></tr><tr class="xRowNormal xMergeUp"><td class="Rrule"/><td colspan="5"/></tr></tbody></table>documented in this encounter</div><h3><a name="id11" href="#toc">Additional Health Concerns</a></h3><div><table><colgroup><col span="2" width="50%"/></colgroup><thead><tr><th>Assessment</th><th>Noted Time</th></tr></thead><tbody><tr class="xRowNormal"><td ID="assessment1">PHQ-9 Depression Total Score: 0</td><td>[REDACTED] 10:38 AM EDT</td></tr><tr class="xRowAlt"><td ID="assessment2">A fall risk assessment has been completed for the patient</td><td>[REDACTED] 10:38 AM EDT</td></tr></tbody></table>documented as of this encounter</div><h3><a name="id12" href="#toc">Care Teams</a></h3><div><table ID="ct67"><colgroup><col span="3" width="25%"/><col width="13%"/><col width="12%"/></colgroup><thead><tr><th>Team Member</th><th>Relationship</th><th>Specialty</th><th>Start Date</th><th>End Date</th></tr></thead><tbody><tr class="xRowNormal"><td><p>[REDACTED], MD</p><p>NPI: [REDACTED]</p><p>[REDACTED]</p><p>Ste# 110</p><p>[REDACTED]</p><p>[REDACTED] (Work)</p><p>[REDACTED] (Fax)</p></td><td>PCP - General</td><td>Internal Medicine</td><td>[REDACTED]</td><td/></tr></tbody></table>documented as of this encounter</div><br/><br/>
</body></html>